Henan Newland Pharmaceutical Co. Ltd. A

301277 · SHE · Healthcare / Drug Manufacturers - Specialty & Generic

8.65CNY-0.22 (-2.48%)

Price History

Full chart

Market Stats

Previous Close8.87

Open8.90

Day Range8.65 – 8.90

52-Week Range8.45 – 13.60

Volume2.94M

Market Cap4.11B

P/E (TTM)38.78

Forward P/E0.00

EPS0.27

Dividend Yield1.91%

Beta0.18

50-Day Avg10.27

200-Day Avg11.13

About

Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge, China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Luwei Zhang
Employees981
HeadquartersEast side of the southern section of Weiwu Road, Changge, China, 461500, China
Websitehttps://www.newlandpharma.com

Leadership

Mr. Luwei ZhangGM & Director · b. 1971
Mr. Qingkui WangFinancial Director & Accounting Supervisor · b. 1979
Mr. Chao LiuDeputy GM & Employee Representative Director · b. 1986
Ms. Yushan XieSecretary of the Board of Directors · b. 1992
Mr. Liying WangDeputy General Manager · b. 1975

Financials

Income Statement

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	433.12M	513.84M	627.36M	651.44M	726.44M	672.38M
Growth (%)	-	+18.64%	+22.09%	+3.84%	+11.51%	-7.44%
Cost of Revenue	236.31M	307.82M	404.01M	391.92M	431.86M	437.63M
Gross Profit	196.81M	206.02M	223.36M	259.51M	294.58M	234.74M
Gross Margin	45.44%	40.09%	35.60%	39.84%	40.55%	34.91%
Operating Expense	49.92M	55.69M	74.08M	98.99M	103.22M	101.39M
Operating Income	146.89M	150.33M	149.27M	160.53M	191.36M	133.36M
Operating Margin	33.91%	29.26%	23.79%	24.64%	26.34%	19.83%
EBITDA	-	-	174.01M	212.38M	235.28M	189.82M
EBITDA Margin	-	-	27.74%	32.60%	32.39%	28.23%
Net Income	118.46M	114.98M	132.30M	158.98M	173.63M	121.25M
Net Income Margin	27.35%	22.38%	21.09%	24.40%	23.90%	18.03%
R&D	20.62M	20.59M	30.00M	51.96M	55.49M	46.18M
R&D as % of Total Revenue	4.76%	4.01%	4.78%	7.98%	7.64%	6.87%
Interest Expense	3.80M	6.71M	6.88M	132.85K	89.32K	211.97K
Interest Expense % of Total Revenue	0.88%	1.30%	1.10%	0.02%	0.01%	0.03%

Balance Sheet

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	521.96M	667.90M	1.53B	1.61B	1.81B	1.78B
Total Liabilities	208.57M	261.53M	174.58M	160.02M	270.69M	228.49M
Total Equity	313.39M	402.53M	1.36B	1.45B	1.54B	1.55B
Cash	36.33M	34.21M	51.13M	270.02M	281.58M	169.00M
Net Debt	73.81M	87.51M	-	-	-	-

Cash Flow

Currency: CNY	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	47.86M	49.08M	82.85M	259.46M	126.76M	116.94M
Capital Expenditure	16.96M	25.40M	74.34M	96.51M	110.79M	101.38M
Free Cash Flow	30.90M	23.68M	8.50M	162.94M	15.97M	15.55M
Dividends Paid	54.46M	36.70M	6.77M	66.68M	80.02M	112.02M
FCF to OCF	64.57%	48.25%	10.26%	62.80%	12.60%	13.30%
Dividend Paid to FCF	176.26%	154.97%	79.64%	40.92%	500.98%	720.31%

Earnings

Report Date	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Mar 31, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Mar 31, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	0.11	0.12	0.12	0.11	0.06	0.14	0.14	0.08	0.08	0.14	0.05	0.04	0.07	0.09	0.06
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Key Statistics & Ratios

Market Cap4.11B

Enterprise Value3.48B

Trailing P/E38.78

Forward P/E0.00

Price / Sales5.78

Price / Book2.67

EPS0.27

Book Value3.91

Revenue (TTM)710.55M

Gross Profit (TTM)202.94M

EBITDA159.86M

Profit Margin14.63%

Operating Margin10.95%

Return on Equity6.72%

Return on Assets3.54%

Shares Outstanding392.08M

Shares Float99.62M

Beta0.18

Dividend Yield1.91%

Dividend Rate0.20

Payout Ratio75.39%

Dividends

20261×

0.20Apr 30, 2026

20251×

0.29Apr 16, 2025

20241×

0.20May 10, 2024

20231×

0.26May 10, 2023

Stock Splits

Apr 16, 20251.4:1
May 10, 20241.4:1
May 10, 20231.5:1